Vic Myer

Vic Myer, Ph.D. is President and Chief Scientific Officer at Chroma Medicine and an Advisor at Atlas Venture. He also serves as an independent Board Member for Velocity Sciences, an advisor to the NIH SCGE, and an SAB member at Obsidian Therapeutics, KromaTid and Life Edit Therapeutics. Previously, he was Chief Technology Officer of Editas Medicine where he led the genome editing platform, CMC and chemistry departments.

At the Novartis Institutes for Biomedical Research, he led a technology-focused target discovery, target validation and lead finding group in the Developmental and Molecular Pathways department for 11 years. Prior to Novartis, Vic focused on industrializing and using ‘omics technologies at Millennium, Akceli and Corning.

He has B.S. from Cornell, a Ph.D. from Yale, and did his post-doc at MIT/The Whitehead.